Invizyne Technologies (NASDAQ:IZTC) vs. Tyra Biosciences (NASDAQ:TYRA) Financial Comparison

Invizyne Technologies (NASDAQ:IZTC) and Tyra Biosciences (NASDAQ:TYRA) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, dividends, analyst recommendations and profitability.

Profitability

This table compares Invizyne Technologies and Tyra Biosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Invizyne Technologies	N/A	N/A	N/A
Tyra Biosciences	N/A	-46.39%	-43.07%

Valuation & Earnings

This table compares Invizyne Technologies and Tyra Biosciences”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Invizyne Technologies	N/A	N/A	N/A	N/A	N/A
Tyra Biosciences	N/A	N/A	-$119.95 million	($2.40)	-10.54

Analyst Recommendations

This is a breakdown of current ratings for Invizyne Technologies and Tyra Biosciences, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Invizyne Technologies	0	0	0	0	0.00
Tyra Biosciences	1	1	12	1	2.87

Tyra Biosciences has a consensus target price of $46.90, suggesting a potential upside of 85.45%. Given Tyra Biosciences’ stronger consensus rating and higher possible upside, analysts plainly believe Tyra Biosciences is more favorable than Invizyne Technologies.

Insider and Institutional Ownership

84.1% of Tyra Biosciences shares are owned by institutional investors. 12.5% of Tyra Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Tyra Biosciences beats Invizyne Technologies on 6 of the 8 factors compared between the two stocks.

About Invizyne Technologies

Invizyne Technologies Inc. is a cell-free enzyme-based biomanufacturing technology company. It redefining biomanufacturing by leveraging cell-free, multi-step, enzyme-based systems to efficiently transform natural or renewable resources into highly sought after biochemicals. Invizyne Technologies Inc. is based in Monrovia, CA.

About Tyra Biosciences

Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in Phase 1/2 clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in Phase 1 clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California.